These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 23667466)

  • 1. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L; Lin N; Li Y
    Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genomic approach to identify molecular pathways associated with chemotherapy resistance.
    Riedel RF; Porrello A; Pontzer E; Chenette EJ; Hsu DS; Balakumaran B; Potti A; Nevins J; Febbo PG
    Mol Cancer Ther; 2008 Oct; 7(10):3141-9. PubMed ID: 18852117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
    He J; Lan X; Liu X; Deng C; Luo H; Wang Y; Kang P; Sun Z; Zhao L; Zhou X
    BMC Cancer; 2023 Mar; 23(1):266. PubMed ID: 36959566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer.
    Duan H; Yang Z; Liang L; Zhou X
    Oncol Lett; 2019 Aug; 18(2):1171-1178. PubMed ID: 31423177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
    Yang X; Tang C; Luo H; Wang H; Zhou X
    Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].
    Zhang Y; Lu H; Xu G
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):635-42. PubMed ID: 25130971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
    Shi P; Yin T; Zhou F; Cui P; Gou S; Wang C
    BMC Cancer; 2014 May; 14():370. PubMed ID: 24885711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt1 enhances CA916798 expression through mTOR pathway.
    Wang YL; Zhu BJ; Qi ZZ; Wang HJ; Zhou XD
    PLoS One; 2013; 8(5):e62327. PubMed ID: 23667466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
    Qi Z; Wang Y; Zhou X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1290-3. PubMed ID: 22985566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA916798 regulates multidrug resistance of lung cancer cells.
    Wang HJ; Yang HP; Zhou XD; Dai XT; Chen YF; Xiong W
    Asian Pac J Cancer Prev; 2011; 12(12):3403-8. PubMed ID: 22471488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.